Exelixis Inc Effective Income Tax Rate Reconciliation, Nondeductible Expense, Amount
Exelixis Inc (EXEL) reported Effective Income Tax Rate Reconciliation, Nondeductible Expense, Amount of $0 for the 12-month period ending 2020-01-03, per its 10-K filed 2020-02-25.
Discontinued › Expense Statement › Income Tax
us-gaap:IncomeTaxReconciliationNondeductibleExpense · last filed 2020-02-25
- Exelixis Inc effective income tax rate reconciliation, nondeductible expense, amount for fiscal 2020 was $0.00.
- Exelixis Inc effective income tax rate reconciliation, nondeductible expense, amount for fiscal 2018 was $0.00, a 100.00% decline from fiscal 2017.
- Exelixis Inc effective income tax rate reconciliation, nondeductible expense, amount for fiscal 2017 was $1.37M, a 48.99% decline from fiscal 2016.
- Exelixis Inc effective income tax rate reconciliation, nondeductible expense, amount for fiscal 2016 was $2.68M.
| Period end | Effective Income Tax Rate Reconciliation, Nondeductible Expense, Amount 12 month |
|---|---|
| 2020-01-03 | $0.00 10-K · filed 2020-02-25 |
| 2018-12-28 | $0.00 10-K · filed 2020-02-25 |
| 2017-12-29 | $1.37M 10-K · filed 2020-02-25 |
| 2016-12-31 | $2.68M 10-K · filed 2017-02-27 |
| 2016-12-30 | $2.68M 10-K · filed 2019-02-22 |
| 2016-01-01 | $3.31M 10-K · filed 2018-02-26 |
| 2015-12-31 | $3.31M 10-K · filed 2017-02-27 |
| 2014-12-31 | $3.60M 10-K · filed 2017-02-27 |
| 2013-12-31 | $3.38M 10-K · filed 2016-02-29 |
| 2012-12-31 | $3.30M 10-K · filed 2015-03-02 |
| 2011-12-31 | $2.81M 10-K · filed 2014-02-20 |
| 2010-12-31 | $0.00 10-K · filed 2013-02-21 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| NEUROCRINE BIOSCIENCES INC (NBIX) | United States | $14.131B | 24.25 |
| HALOZYME THERAPEUTICS, INC. (HALO) | United States | $13.083B | 21.59 |
| Twist Bioscience Corp (TWST) | United States | $11.540B | -47.21 |
| BIO-TECHNE Corp (TECH) | United States | $11.379B | 74.68 |
| REPLIGEN CORP (RGEN) | United States | $10.755B | 185.31 |
| Krystal Biotech, Inc. (KRYS) | United States | $10.210B | 45.56 |
| Kymera Therapeutics, Inc. (KYMR) | United States | $9.631B | -31.69 |
| ImmunityBio, Inc. (IBRX) | United States | $9.157B | -9.29 |
| Vaxcyte, Inc. (PCVX) | United States | $8.466B | -7.91 |
| Immunovant, Inc. (IMVT) | United States | $7.028B | -14.78 |